8-K: Stepan Company Reports Mixed Q4 2024 Results, Announces Dividend Increase

Stepan Company's Q4 2024 results show a mix of improved net income but a decline in adjusted net income, alongside the announcement of a raised quarterly dividend.

Summary

• Stepan Company reported its Q4 and full-year 2024 financial results on February 19, 2025.
• Q4 net income was $3.4 million, compared to a $1.2 million net loss in the prior year.
• Adjusted net income for Q4 was $2.8 million, a 63% decrease year-over-year, attributed to higher pre-commissioning expenses at the Pasadena, Texas facility, a one-time tax proceeding reserve in Latin America, and CEO transition expenses.
• Q4 EBITDA was $35.8 million, while adjusted EBITDA was $35.0 million, representing a 39% increase and a 7% decrease, respectively.
• Global sales volume decreased by 1% year-over-year, with surfactant growth offset by polymer weakness.
• Cash from operations was $68.3 million, and free cash flow was $32.1 million for the quarter.
• The company achieved $13.0 million in pre-tax cost-out savings during the quarter.
• Full-year net income was $50.4 million, a 25% increase from the previous year.
• Full-year adjusted net income was $50.5 million, flat compared to the prior year.
• Full-year EBITDA was $186.9 million, and adjusted EBITDA was $187.0 million, up 13% and 4% respectively.
• Full-year global sales volume increased by 1%.
• Full-year free cash flow was $39.3 million, compared to a negative $85.5 million in the prior year.
• The company delivered $48.0 million in cost-out savings for the year.
• The Board of Directors declared a quarterly cash dividend of $0.385 per share, payable on March 14, 2025, to stockholders of record as of March 3, 2025.
• This marks the 57th consecutive year of dividend increases.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While net income and some segments show growth, adjusted net income declined, and there are ongoing challenges. The dividend increase and positive outlook provide some optimism.

Positives

• Net income improved significantly in Q4 2024 compared to the previous year.
• Full-year net income increased by 25%.
• The company achieved substantial cost-out savings.
• Stepan increased its dividend for the 57th consecutive year.
• The Pasadena facility is nearing completion and is expected to contribute to future growth.
• Free cash flow improved significantly year-over-year.

Negatives

• Adjusted net income decreased by 63% in Q4 2024 due to specific one-time expenses.
• Global sales volume decreased slightly by 1% in Q4 2024.
• Polymer sales volume declined by 9% in Q4 2024.
• Adjusted EBITDA decreased by 7% in Q4 2024.

Risks

• The company faces risks related to accidents and unplanned production shutdowns.
• Reduced demand due to customer product reformulations or new technologies could impact sales.
• Global competition and volatility of raw material and energy costs pose ongoing challenges.
• International business risks, including currency exchange rate fluctuations, could affect profitability.
• The company's debt covenants could restrict financial flexibility.

Future Outlook

Stepan expects Adjusted EBITDA to improve in all reporting segments in 2025, driven by volume growth, improved product mix, and cost-out initiatives; the Pasadena facility startup is expected in Q1 2025, contributing to volume growth and supply chain savings; the company anticipates full-year Adjusted EBITDA and Adjusted Net Income growth and positive free cash flow in 2025.

Management Comments

• Full year Adjusted EBITDA grew 4% versus prior year despite several one-time events that negatively impacted earnings and the pre-operating expenses in our new Pasadena, site, said Luis E. 1 Rojo, President and Chief Executive Officer.
• Surfactants and Specialty Products delivered strong double-digit Adjusted EBITDA growth, partially offset by demand weakness in Polymers.
• Overall, global sales volume grew 1%, driven by 2.5% growth in our Surfactant business.
• We are encouraged by the Surfactant growth within several of our key strategic end markets.
• We delivered $39 million of free cash flow, which was in line with our expectations, and we increased our dividend for the 57th consecutive year.
• We completed the majority of our new Pasadena, Texas site which is critical to growing our alkoxylation business.
• Our strong foundation, combined with the cost reductions and strategic investments we have made, position us well to deliver future growth.
• We believe Adjusted EBITDA will improve in all of our reporting segments.
• We are optimistic that Polymer demand will increase as we execute our innovation and growth plans.
• We believe our Surfactant business will experience continued growth in our key strategic end markets.
• As previously announced, we expect our Pasadena facility will start up in the first quarter of 2025 and enable us to deliver volume growth and Supply Chain savings during the year.
• We believe we are positioned well to deliver full year Adjusted EBITDA and Adjusted Net Income growth and positive free cash flow in 2025.

Industry Context

Stepan's performance reflects broader trends in the chemical industry, with strong demand in specific surfactant end-markets like agriculture and oilfield solutions contrasting with weakness in polymers due to economic uncertainty and competitive pressures; the company's strategic investments in new facilities and cost-saving initiatives align with industry efforts to improve efficiency and profitability.

Comparison to Industry Standards

• Comparing Stepan to companies like BASF, Dow, and Evonik, Stepan's surfactant business growth aligns with the industry's focus on specialty chemicals and sustainable solutions.
• However, the decline in Stepan's polymer segment mirrors the challenges faced by other chemical companies in commodity polymer markets due to fluctuating raw material costs and global economic slowdown.
• Stepan's cost-saving initiatives are comparable to similar programs implemented by its peers to enhance profitability and competitiveness.
• The Pasadena facility investment is in line with the industry's trend of expanding capacity in strategic growth areas like alkoxylation.

Stakeholder Impact

• Shareholders will benefit from the increased dividend.
• Employees may be affected by cost-out initiatives and the CEO transition.
• Customers can expect continued supply of surfactants, polymers, and specialty products.
• Suppliers may experience changes in demand based on Stepan's production and sales volumes.
• Creditors will monitor Stepan's debt levels and financial performance.

Next Steps

• Start-up of the Pasadena facility in Q1 2025.
• Focus on accelerating business strategies through improved execution.
• Drive consistent volume growth, margin improvement, and free cash flow generation.
• Execute innovation and growth plans to increase Polymer demand.
• Continue growth in key strategic Surfactant end markets.

Key Dates

Keywords

Stepan Company, financial results, dividends, surfactants, polymers, specialty products, EBITDA, net income, sales volume, Pasadena facility